<DOC>
	<DOCNO>NCT00561418</DOCNO>
	<brief_summary>RATIONALE : Vorinostat may stop growth cancer cell block enzymes need cell growth , may stimulate immune system stop cancer cell grow . PURPOSE : This phase I trial study side effect best dose vorinostat stem cell transplant treat patient high-risk lymphoma .</brief_summary>
	<brief_title>Vorinostat After Stem Cell Transplant Treating Patients With High-Risk Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - To assess dose-limiting nonhematologic toxicity prolong administration vorinostat ( SAHA ) administer autologous peripheral blood stem cell transplantation patient high-risk lymphoma . Secondary - To determine , preliminarily , clinical activity assess overall survival progression-free survival . - To evaluate effect vorinostat immune reconstruction acetylation . - To obtain pilot data regard association vorinostat patient quality life inflammatory cytokine production peripheral blood mononuclear cell . OUTLINE : This dose-escalation study vorinostat ( SAHA ) . Approximately 60 day autologous hematopoietic stem cell transplantation ( HSCT ) , patient receive oral vorinostat daily day 1-21 . Treatment repeat every 28 day 11 course absence unacceptable toxicity disease progression . Blood bone marrow sample collect periodically laboratory correlative study comprise immune reconstitution assay , regulatory T-cell expansion analysis , H3 H4 acetylation immunohistochemistry , cytokine bead array quantify interleukin ( IL ) -2 , IL-4 , IL-5 , IL-6 , IL-10 , tumor necrosis factor alpha interferon gamma . Quality life correlative study measure questionnaire periodically . After completion study treatment , patient follow least 30 day .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Must receive BEAM ( cytarabine , etoposide , melphalan , carmustine ) condition autologous stem cell transplantation follow highrisk lymphoma : Diffuse large Bcell lymphoma define : Induction failure response salvage therapy Relapse le one year completion induction therapy Elevated lactate dehydrogenase ( LDH ) relapse Stage III/IV disease relapse Positive PET scan induction salvage therapy Age ≤ 75 ≥ 60 year Follicular lymphoma define : Progressive disease two prior regimen Transformed aggressive lymphoma still chemotherapy sensitive Not felt good candidate allogeneic transplantation Hodgkin lymphoma define : Primary refractory disease Relapse le one year completion induction therapy Relapse PETpositive disease salvage therapy Relapsed refractory felt good candidate allogeneic transplantation Mantle cell lymphoma Chemotherapysensitive disease induction therapy Chemotherapysensitive relapse disease felt good candidate allogeneic transplantation Tcell nonHodgkin lymphoma ( NHL ) Peripheral Tcell lymphoma otherwise specify one follow diagnosis : High LDH Marrow involvement Age &gt; 60 year Low platelet count Relapsed chemotherapysensitive disease Angioimmunoblastic lymphadenopathy dysproteinemia Anaplastic lymphoma kinasenegative anaplastic NHL Enteropathyassociated Tcell NHL Natural killer ( NK ) /Tcell NHL stage III/IV disease diagnosis NK blastic NHL PATIENT CHARACTERISTICS : ECOG ( Eastern Cooperative Oncology Group ) /WHO performance status 02 ANC ( absolute neutrophil count ) ≥ 1,000/μL Platelet count ≥ 75,000/μL Total bilirubin ≤ 1.5 mg/dL AST ( aspartate aminotransferase ) /ALT ( Alanine transaminase ) ≤ 2 x upper limit normal ( ULN ) Serum creatinine ≤ 1.5 x ULN OR creatinine clearance ≥ 50 mL/min No severe uncontrolled systemic illness Patients must able swallow capsule Negative pregnancy test Not pregnant nursing Fertile patient must use least two adequate barrier method contraception study 90 day completion study therapy No malignancy within past 5 year nonmelanoma skin cancer , carcinoma situ cervix , malignancy consider physician less 30 % risk relapse No congenital long QT syndrome No significant history uncontrolled cardiac disease ( i.e. , uncontrolled hypertension , unstable angina , myocardial infarction within past 6 month , uncontrolled congestive heart failure ) No active bacterial , fungal , viral infection No known HIV infection No active hepatitis B and/or hepatitis C infection No medical condition , include mental illness substance abuse , deem Investigator ( ) interfere patient 's ability sign inform consent , cooperate participate study , interfere interpretation result PRIOR CONCURRENT THERAPY : Recovered majority toxicity autologous transplantation ( must return pretransplant baseline great grade I extramedullary toxicity Common Toxicity Criteria Adverse Effects [ CTCAE 3.0 ] ) No prior treatment histone deacetylase ( HDAC ) inhibitor ( e.g. , depsipeptide , MS275 , LAQ824 , belinostat , valproic acid ) More 4 week since prior concurrent class Ia , Ib , Ic antiarrhythmic drug No concurrent antineoplastic chemotherapy biologic therapy No concurrent radiotherapy , unless local control bone pain Irradiated area pain management small possible lesion within irradiated field use response No concurrent use complementary alternative medicine would confound interpretation toxicity antitumor activity vorinostat ( SAHA )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage III adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>small intestine lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
</DOC>